Temperature stable vaccine formulations
Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.
1. A method of preparing a stable lyophilized vaccine, the method comprising:
(a) exchanging at least part of a liquid component of a first composition comprising at least one Anthrax antigen adsorbed to an aluminum adjuvant with a second liquid component comprising (i) a non-reducing sugar to create a second composition that comprises at least 20% (w/v) non-reducing sugar and 75 to 750 μg/ml Anthrax antigen, (ii) a non-reducing sugar and an amino acid to create a second composition that comprises at least 10% (w/v) non-reducing sugar and 75 to 750 μg/ml Anthrax antigen, or (iii) a non-reducing sugar and a surfactant to create a second composition that comprises at least 15% (w/v) non-reducing sugar and 75 to 750 μg/ml Anthrax antigen;
wherein the exchanging comprises (x) separating the liquid component of the first composition from a solid component of the first composition; (y) centrifuging the first composition and separating at least part of the liquid component of the first composition from a pelleted component of the first composition; or (z) filtering the first composition to separate at least part of the liquid component of the first composition from a solid component of the first composition;
wherein the second liquid component is prepared by adding the non-reducing sugar, the amino acid, and/or the surfactant of (i), (ii) or (iii) to at least a portion of the liquid component separated from the first composition according to (x), (y), or (z); and
wherein the creation of the second composition comprises combining (1) the second liquid component and (2) the solid component or the pelleted component of the first composition; and
(b) lyophilizing the second composition.
2. The method of claim 1 , wherein the second liquid component comprising (i) or (ii) further comprises a surfactant.
3. The method of claim 1 , wherein the exchanging comprises centrifuging the first composition and separating at least part of the liquid component of the first composition from the pelleted component of the first composition.
4. The method of claim 1 , wherein the aluminum adjuvant is aluminum hydroxide, aluminum phosphate or aluminum sulfate.
5. The method of claim 4 , wherein the first or second composition contains about 0.5 to about 1.5 mg/ml aluminum hydroxide.
6. The method of claim 1 , wherein the surfactant is selected from the group consisting of polysorbate 80 and polysorbate 20.
7. The method of claim 1 , wherein the non-reducing sugar is trehalose, sucrose, or a combination thereof.
8. The method of claim 1 , wherein the second composition contains about 15-40% (w/v) non-reducing sugar.
9. The method of claim 1 , wherein the Anthrax antigen is a protective antigen having at least about 80% identity to the polypeptide of SEQ ID NO: 2.
10. The method of claim 1 , wherein the Anthrax antigen is a cell-free filtrate from an avirulent B. anthracis strain.
11. The method of claim 10 , wherein the avirulent B. anthracis strain is V770-NP1-R.
12. The method of claim 1 , wherein the first composition or second composition is an anthrax vaccine.
13. The method of claim 1 wherein the second composition comprises at least one amino acid.
14. The method of claim 13 wherein the at least one amino acid is selected from the group consisting of arginine, alanine, proline and glycine.
15. The method of claim 14 , wherein the second composition contains alanine or arginine, at about 0.5-4% (w/v) or about 2% (w/v).